Gilead Sciences | GILD - Current Liabilities


Gilead Sciences reported $11.02B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
J&J USD 55.46B 562M Sep/2026
Merck USD 27.73B 786M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026